News & Updates
Filter by Specialty:

RSV vaccine plus flu or COVID-19 shots safe, feasible in older adults
Coadministration of mRNA-1345, a respiratory syncytial virus (RSV) vaccine, with an influenza (flu) or a COVID-19 vaccine in older adults exhibits good tolerability and has an acceptable reactogenicity profile, according to a US study presented at ESCMID Global Congress 2024.
RSV vaccine plus flu or COVID-19 shots safe, feasible in older adults
13 May 2024
Patritumab deruxtecan may improve survival in EGFR-mutated NSCLC
Treatment with patritumab deruxtecan (HER3-DXd) confers survival benefits on patients with epidermal growth factor receptor (EGFR)-mutated nonsmall-cell lung cancer (NSCLC) following EGFR tyrosine kinase inhibitor (TKI) and platinum-based chemotherapy, results of a phase I study have shown.
Patritumab deruxtecan may improve survival in EGFR-mutated NSCLC
10 May 2024
Probiotics may improve QoL in lung cancer patients
In lung cancer patients undergoing platinum-based doublet chemotherapy, oral compound probiotic supplements may improve their quality of life (QoL) and relieve gastrointestinal (GI) side effects related to their chemo regimen.
Probiotics may improve QoL in lung cancer patients
08 May 2024
Lung cancer screening tied to reduced mortality
In an observational study conducted in Poland, individuals who participated in a low-dose computed tomography (LDCT) lung cancer screening programme had a reduction in all-cause mortality compared with a matched control group extracted from a general Polish cohort.
Lung cancer screening tied to reduced mortality
07 May 2024
Prognosis role of blood urea nitrogen to serum albumin ratio established in IPAH
A higher ratio of blood urea nitrogen to serum albumin is indicative of worse outcomes and disease severity in patients with idiopathic pulmonary arterial hypertension (IPAH), according to a study.
Prognosis role of blood urea nitrogen to serum albumin ratio established in IPAH
03 May 2024
Speeding COVID-19 symptom recovery may not fall within the realm of nirmatrelvir–ritonavir
Treating COVID-19 patients who had been vaccinated or did not have risk factors for severe disease with ritonavir-boosted nirmatrelvir (nirmatrelvir–ritonavir) did not expedite the time to symptom alleviation, reported investigators in the EPIC-SR trial.